Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
About Abeona Therapeutics Inc.
- NASDAQ: $ABEO
- Notified: $3.76
- 07:30 EDT
